Cure My Disease

Don't miss your cure!

 Log in / Sign up

Can genes explain sudden cardiac death in young athletes?

NCT ID NCT06642168

Knowledge-focused Sponsor: Rennes University Hospital Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 25, 2026 · Last updated Aug 26, 2026 · Updated 1 time

Summary

This study is a national registry in France that will follow young people aged 12 to 35 who experience sudden cardiac arrest or death during sports. Researchers will perform thorough medical investigations, including autopsies and whole exome genetic testing, to try to find the underlying cause. The goal is to reduce the number of unexplained cases and help prevent these tragic events in families.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Whole exome sequencing to detect myocardial genetic mutations
What this could lead to
If successful, this could identify genetic causes behind many unexplained sudden cardiac arrests in young athletes, enabling family screening and prevention.
What could go wrong
This is an observational registry, not a treatment trial, so it won't directly test a therapy. Genetic findings may not explain all cases, and the study's small size may limit broader conclusions.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Participants

About 80 people

The number the study aims to enrol. It can still change while the study runs.

Started

Oct 2024

Expected to finish

Jan 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Who is studied

The study will include French victims of sports-related SCA/SCD between the ages of 12 and 35, as well as their first-degree relatives over 12 years of age, when applicable.

Ages

12 to 35 years

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Victims of SCA: * Aged between 12 and 35 years * No known cardiovascular pathology * Experienced a sudden and non-traumatic SCA during or within one hour of participating in sports activities (leisure, training, or competition) * For resuscitated victims (SCA group): A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, organs, or authorities responsible for assisting or representing them if they are unable to express their wishes). * For non-resuscitated victims (SCD group): A person who has not formally objected to the reuse of their medical data during their lifetime. * First-Degree Relatives: * A person or legal representative who does not oppose participation in the research after being informed about the study (including individuals, bodies, or authorities responsible for assisting or representing them if they are unable to express their wishes). Non-Inclusion Criteria: * For resuscitated SCA cases, individuals weighing less than 20 kg * Victims or legal representatives who are subject to legal protection or deprived of their liberty

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Sudden cardiac arrest are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

Death, Sudden, Cardiac sudden arrhythmia death syndrome sudden cardiac arrest

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Sudden cardiac arrest Sudden cardiac death

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    26 sites. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • APHM Hôpitaux universitaires de Marseille

    RECRUITING

    Marseille, 13364, France

  • APHP Hôpital Bichat

    NOT_YET_RECRUITING

    Paris, France, 75877, France

  • APHP Hôpital Européen Georges Pompidou

    RECRUITING

    Paris, France, 75908, France

  • APHP Hôpital Henri-Mondor

    NOT_YET_RECRUITING

    Créteil, 94010, France

  • APHP Hôpital Pitié-Salpêtrière

    RECRUITING

    Paris, 75651, France

  • CHRU Lille

    RECRUITING

    Lille, 59037, France

  • CHRU Montpellier

    RECRUITING

    Montpellier, 34295, France

  • CHRU Nancy

    NOT_YET_RECRUITING

    Nancy, 54035, France

  • CHRU Strasbourg

    NOT_YET_RECRUITING

    Strasbourg, 67091, France

  • CHRU Tours

    RECRUITING

    Tours, 37044, France

  • CHU Bordeaux

    RECRUITING

    Bordeaux, 33600, France

  • CHU Brest

    NOT_YET_RECRUITING

    Brest, 29609, France

  • CHU Caen

    RECRUITING

    Caen, 14033, France

  • CHU Clermont-Ferrand

    RECRUITING

    Clermont-Ferrand, 63003, France

  • CHU Dijon Bourgogne

    NOT_YET_RECRUITING

    Dijon, 21079, France

  • CHU Nantes

    RECRUITING

    Nantes, 44093, France

  • CHU Nîmes

    NOT_YET_RECRUITING

    Nîmes, France, 30029, France

  • CHU Poitiers

    RECRUITING

    Poitiers, 86000, France

  • CHU Reims

    NOT_YET_RECRUITING

    Reims, 51092, France

  • CHU Rennes

    RECRUITING

    Rennes, France, 35000, France

  • CHU Rouen

    NOT_YET_RECRUITING

    Rouen, 76031, France

  • CHU Saint-Etienne

    RECRUITING

    Saint-Etienne, 42100, France

  • CHU Toulouse

    RECRUITING

    Toulouse, 31059, France

  • CHU de Grenoble Alpes

    NOT_YET_RECRUITING

    Grenoble, 38700, France

  • CHU de Nice

    RECRUITING

    Nice, 06003, France

  • Hospices Civils de Lyon

    NOT_YET_RECRUITING

    Lyon, 69229, France

More trials for these conditions

Other studies related to the condition(s) this trial covers.